Vanguard Group’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-448,330
| Closed | -$62.8K | – | 4469 |
|
|
2024
Q1 | $62.8K | Hold |
448,330
| – | – | ﹤0.01% | 4288 |
|
|
2023
Q4 | $65.2K | Sell |
448,330
-608,547
| -58% | -$94.5K | ﹤0.01% | 4349 |
|
|
2023
Q3 | $185K | Sell |
1,056,877
-372,109
| -26% | -$462K | ﹤0.01% | 4262 |
|
|
2023
Q2 | $4.46M | Buy |
1,428,986
+362,607
| +34% | +$1.08M | ﹤0.01% | 3361 |
|
|
2023
Q1 | $2.73M | Buy |
1,066,379
+547,147
| +105% | +$1.13M | ﹤0.01% | 3567 |
|
|
2022
Q4 | $774K | Buy |
519,232
+85,236
| +20% | +$138K | ﹤0.01% | 3991 |
|
|
2022
Q3 | $755K | Sell |
433,996
-1,978
| -0.5% | -$2.8K | ﹤0.01% | 4085 |
|
|
2022
Q2 | $567K | Sell |
435,974
-1,409
| -0.3% | -$2.41K | ﹤0.01% | 4258 |
|
|
2022
Q1 | $1.04M | Sell |
437,383
-31,516
| -7% | -$82.1K | ﹤0.01% | 4194 |
|
|
2021
Q4 | $2.15M | Sell |
468,899
-12,625
| -3% | -$41.7K | ﹤0.01% | 4004 |
|
|
2021
Q3 | $3.9M | Hold |
481,524
| – | – | ﹤0.01% | 3801 |
|
|
2021
Q2 | $4.73M | Sell |
481,524
-25,013
| -5% | -$203K | ﹤0.01% | 3637 |
|
|
2021
Q1 | $4.47M | Buy |
506,537
+4,655
| +0.9% | +$51.1K | ﹤0.01% | 3585 |
|
|
2020
Q4 | $5.13M | Buy |
501,882
+134,366
| +37% | +$1.47M | ﹤0.01% | 3343 |
|
|
2020
Q3 | $3.32M | Sell |
367,516
-1,180
| -0.3% | -$9.35K | ﹤0.01% | 3332 |
|
|
2020
Q2 | $2.63M | Buy |
368,696
+208,374
| +130% | +$2.21M | ﹤0.01% | 3356 |
|
|
2020
Q1 | $1.52M | Buy |
160,322
+84,581
| +112% | +$1.09M | ﹤0.01% | 3374 |
|
|
2019
Q4 | $997K | Buy |
+75,741
| New | +$924K | ﹤0.01% | 3640 |
|
Other funds holding GRTX
Vanguard Group's GRTX Position: Q2 2024 in Review
Vanguard Group sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q2 2024, closing a stake of 448,330 shares — an estimated $62.8K sold.
Vanguard Group first reported a position in GRTX in Q4 2019 and held it in 18 quarters. The position peaked at $5.13M in Q4 2020. 1 fund tracked by Wall St. Rank holds GRTX as of Q2 2024.
- Vanguard Group reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Vanguard Group sold 448,330 Galera Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $62.8K.
- Vanguard Group first reported a position in Galera Therapeutics, Inc. Common Stock in Q4 2019 and held it in 18 quarters.
- Vanguard Group's Galera Therapeutics, Inc. Common Stock position peaked at $5.13M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q2 2024.
Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.